• Annexon flagged an ASRS 2026 presentation on Phase 2 ARCHER data for vonaprument in geographic atrophy, highlighting baseline factors tied to BCVA 15-letter loss.
• Results are intended to guide patient selection for the ongoing Phase 3 ARCHER II trial, with topline pivotal data expected in Q4 2026.
• Vonaprument is a non-pegylated Fab designed to block C1q, targeting neurodegeneration pathways in dry age-related macular degeneration with geographic atrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607141605PRIMZONEFULLFEED9762177) on July 14, 2026, and is solely responsible for the information contained therein.